

Declaration of interests register

Medical Technologies Advisory Committee

Publication Date: 25/11/2019

Topic: MT323 gammaCore for cluster headache

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
<i>Dr Mike Burrows</i>	Committee member	Non-financial professional	<i>Has worked with the company (electroCore) in his current and previous role to provide advice on how to approach the NHS market</i>	2015	May 2019	2018	Complete exclusion – reviewed by MTAC Chair and Medical Technologies Evaluation Programme Manager
<i>Dr Benjamin Wakerley</i>	Expert adviser	Indirect	<i>Runs the Oxford headache symposium, an annual non-profit making headache meeting that has been hosted in Oxford for the past 16 years at Worcester college.</i> <i>Dr Wakerley has organised the meeting since 2016 and it is attended by neurologists, GPs and nurses with specialist interest in headache. Typically it is sponsored by other</i>	2016	June 2019	2016	No action other than the process of open declaration

			<i>pharmaceutical companies related to headache – e.g. Allergan, Norvatis, Cefaly.</i>				
<i>Dr Brendan Davies</i>	Expert adviser	Non-financial professional	<i>Co-author on a published paper in the journal of Headache and Pain on the real world use of the GammaCore device for the treatment of 30 patients with cluster headache in the UK. Published Nov 2018.</i>	<i>March 2018</i>	<i>January 2019</i>	<i>November 2018</i>	Partial exclusion – reviewed by Medical Technologies Evaluation Programme Manager
		Indirect	<i>Currently acting as a UK principal investigator in commercial study of Galcanezumab, an anti-CGRP monoclonal antibody vs. placebo as a potential treatment for cluster headache.</i>	<i>September 2017</i>	<i>January 2019</i>	<i>ongoing</i>	No action other than the process of open declaration